BioMarin Announces Fourth Quarter and Record Full-year 2019 Financial Results
BioMarin Pharmaceutical Inc. on 6ix
Story so far
Earlier from BioMarin Pharmaceutical
- BioMarin's Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 2020
- BioMarin Announces CFO Succession
- BioMarin to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast on Wednesday, February 26 at 4: 30pm ET
- BioMarin, Pioneer in Phenylketonuria, to Begin Clinical Trial with BMN 307 Gene Therapy
- BioMarin Announces New England Journal of Medicine Publishes 3 Years of Follow-up Data in Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A
Later from BioMarin Pharmaceutical
- BioMarin Plans Regulatory Submissions for Marketing Authorization of Vosoritide to Treat Children with Achondroplasia in 3Q 2020 in both US and Europe
- BioMarin to Host First Quarter 2020 Financial Results Conference Call and Webcast on Thursday, April 30 at 4: 30pm ET
- BioMarin Appoints Global Pharmaceutical Veteran C. Greg Guyer, Ph.D., to Chief Technical Officer, Executive Vice President of Global Manufacturing and Technical Operations, Effective May 4
- BioMarin Updates Timing of First Quarter 2020 Financial Results Conference Call and Webcast to Wednesday, April 29 at 4: 15pm ET
- BioMarin Announces First Quarter 2020 Total Revenue Growth of 25% to $502 million
Follow BioMarin Pharmaceutical into a list and get an email when it puts out news.
Follow BioMarin Pharmaceutical